Inclusion Criteria:

          -  Patient has platinum-sensitive, recurrent ovarian, fallopian-tube or peritoneal
             cancer. Platinum sensitivity is defined as complete clinical remission after frontline
             chemotherapy lasting greater than 6 months

          -  Patient has completed at least 2 courses of platinum-based chemotherapy with a PR or
             CR as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.139 or a
             CA-125 response, according to Gynecological Cancer InterGroup (GCIG) criteria40

          -  BRCA testing required (results not needed for registration)

          -  ECOG performance status score of 0, 1, or 2 (See Appendix A)

          -  Life expectancy greater than 6 months

          -  Normal organ and marrow function as defined: Absolute neutrophil count (ANC) ≥ 1.5 x
             109/L; Platelets ≥ 100 x 109/L; Hemoglobin (Hgb) ≥ 8 g/dL (blood transfusions to reach
             this amount are allowed); Serum creatinine ≤ 1.5 mg/dL; Total serum bilirubin ≤ 1.5 x
             ULN; AST and ALT ≤ 2.5 x ULN

          -  Able to take oral medication

          -  Not pregnant and not breastfeeding

          -  Able to understand and willingness to sign a written informed consent document

          -  Patients must be enrolled within 8 weeks of completing last cycle of chemotherapy

        Exclusion Criteria:

          -  Patient has had a prior invasive malignancy diagnosed within the last five years
             (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix or
             breast [3] has been without evidence of invasive disease for greater than 3 years)

          -  Patients receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to olaparib

          -  Uncontrolled intercurrent illness that could affect their participation in the study
             including, but not limited to, ongoing or active infection; symptomatic congestive
             heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately
             controlled hypertension; significant pulmonary disease including dyspnea at rest,
             patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Impairment of gastrointestinal function or disease that may significantly alter the
             absorption of olaparib

          -  Patients who have received prior treatment with a PARP inhibitor

          -  History of noncompliance to medical regimens